| REVIEW ARTICLE |
|
| Year : 2022 | Volume
: 6
| Issue : 1 | Page : 21-32 |
|
|
Recent insights of SARS-CoV-2 potential inhibitors
Mohd Faheem1, Vinay Kumar Singh1, Abhishek Srivastava2
1 Department of Chemistry, Dr. Shakuntala Misra National Rehabilitation University, Lucknow, Uttar Pradesh, India
2 Department of Chemistry, GLA University, Mathura, Uttar Pradesh, India
Correspondence Address:
Abhishek Srivastava
Department of Chemistry, GLA University, Mathura - 281 004, Uttar Pradesh
India
Vinay Kumar Singh
Department of Chemistry, Dr. Shakuntala Misra National Rehabilitation University, Lucknow, Uttar Pradesh
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/bbrj.bbrj_229_21
|
|
|
The year of 2019–2021 is emergency that the world is facing due to the spread of 2019-nCoV which has created a very critical condition in human society, known as COVID-19. The complex virus belongs to the family of coronaviridae and genera betacoronavirus and spreads through human interaction. The common symptoms observed in infected are a sudden rise in body temperature within 1st to 9th day of infection, problems around the neck and throat from the start of the infection followed by the spread of infection into the lungs that cause novel coronavirus pneumonia and kidney failure. Many of the receptor proteins of the severe acute respiratory syndrome coronavirus (SARS-CoV-2) and target proteins of the human cells are responsible for endocytosis such as main protease or 3C-like protease, RNA polymerase, and spike protein. These proteins play a vital role in the life cycle of SARS-CoV-2. Many of the computational designed drugs and docking-based drugs are reported as anti-COVID-19. Many of the drugs show strong potent activity against this deadly virus. This study demonstrates the synthetic and computational designed approach, drugs, and compounds for the potential inhibition of the SARS-CoV-2 virus. The review will be helpful in finding a new approach of a drug as an inhibitory receptor of SARS-CoV-2.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
